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The treatment of amblyopia, particularly anisometropic (difference in refractive correction)
and/or strabismic (turn of one eye) amblyopia has long been a challenge for many clini-
cians. Achieving optimum outcomes, where the amblyopic eye reaches a visual acuity
similar to the fellow eye, is often impossible in many patients. Part of this challenge has
resulted from a previous lack of scientific evidence for amblyopia treatment that was
highlight by a systematic review by Snowdon et al. in 1998. Since this review, a number of
publications have revealed new findings in the treatment of amblyopia. This includes the
finding that less intensive occlusion treatments can be successful in treating amblyopia. A
relationship between adherence to treatment and visual acuity has also been established
and has been shown to be influenced by the use of intervention material. In addition, there
is growing evidence of that a period of glasses wearing only can significantly improve vi-
sual acuity alone without any other modes of treatment. This review article reports find-
ings since the Snowdon's report.Unilateral amblyopia is a loss in visual function in one eye in
comparison to the other and is often caused by other associ-
ated factors that force the visual system to prefer one eye over
another [1]. The most common of these factors is a difference
in refractive error between the two eyes, usually in spherical
correction (anisometropic amblyopia) and/or a strabismus
(strabismic amblyopia). Many other forms of unilateral
amblyopia occur as a result of pathological changes in the
structure in or around the eye such as unilateral cataracts or
ptosis (stimulus deprivation amblyopia). A challenge in theoup, University of Leice
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mons.org/licenses/by-nctreatment of amblyopia is that there is often no apparent
structural reason why there is a limitation of vision and yet
many amblyopes, after several years of amblyopia treatment,
fail to reach successful outcomes.
Since as early as the 1st century AD [2] covering of the
dominant eye to increase visual acuity in the amblyopic eye,
now referred to as occlusion therapy, has been suggested as
the standard form of treatment in anisometropic and stra-
bismus amblyopia. However, it was not until the Snowdon's
report [3] in 1998 that it became apparent that evidence-basedster, RKSCB, Leicester Royal Infirmary, Leicester LE2 7LX, UK.
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ing. As a result of these findings, there has been a significant
increase in publications of randomized controlled studies in
amblyopia. This review will explore the new findings since
this report and discuss future areas of interest for amblyopia
treatment.Refractive therapy
In childrenwith amblyopia, in particular when a strabismus is
present, it is recommended that full refractive correction
should be prescribed [4]. However, there is some confliction
within literaturewith regards prescribing full prescription due
to its possible effects on emmetropization. In a study by
Atkinson et al. [5] they found that thosewhowere prescribed a
partial correction in comparison to thosewhowere prescribed
no refractive correction the process of emmetropization was
the same. In contrast, a randomized control trial (RCT) study
by Ingram et al. (n ¼ 287) [6], showed that those who were
prescribed full correction from the age of 6 months and had
good adherence to glasses wear, the effect on emmetropiza-
tion was significantly delayed in comparison to those who
were poor compliers or were not prescribed any refractive
correction. Further investigation regarding the amount of
hyperopia that affects emmetropization is still required.
In 2002, Moseley et al. [7] reported the results of 13 aniso-
metropic and strabsimic amblyopes who were prescribed
refractive correction only, they showed for the first time that
amblyopic subjects can gain significant improvements in vi-
sual outcome with refractive correction alone. In a later study
[8], 14 of 65 amblyopic subjects (interocular difference in vi-
sual acuity of >0.1) had a resolution of their amblyopia with
glasses alone, and no further treatment was required. The
mean improvement in visual acuity for the 65 patients was
0.18 LogMAR with the majority of cases achieving maximum
improvement within the first 18 weeks of wearing refractive
correction. There was no significant difference in the level of
improvement between different types of amblyopia, (aniso-
metropic, strabismic or strabismus with anisometropia)
p ¼ 0.29. However, a recent survey of orthoptists reported 94%
prescribe a period of refractive correction before implement-
ing further treatment, although this is lower for strabismic
(75%) or strabismic and anisometropic amblyopia (79%) [9].
This period of refractive correction is also commonly referred
to as refractive adaptation or refractive treatment [8]. Limi-
tations of this study include no randomized control group and
the inclusion of patients with an intraocular difference of 0.1
which is not often described as amblyopia.
Since this study, a number of additional studies have
confirmed that this period of refractive treatment does occur
in anisometropic and/or strabismic amblyopes [10e12]. It has
been also reported to have a greater effect in those with better
baseline stereopsis, milder forms of anisometropic amblyopia
and those with a worse baseline visual acuity in strabismus
with anisometropia and strabismic patients. The least likely
type of amblyopia to respond to refractive adaption has been
reported to occur in strabismus with anisometropia ambly-
opia. There is also a wide variance in the length of time
required to achieve the maximum outcome of refractiveadaptation [12]. One of the possible factors is the influence of
adherence to glasses wear. An unpublished pilot study
including 26 patients [13], has revealed variable adherence to
glasses wear. It has also shown a strong doseeresponse rela-
tionship between adherence and visual outcome (r ¼ 0.76,
p ¼ 0.0001). Further work in this area with a larger cohort is
needed to explore the relationships between glasses wearing,
refractive adaption and visual outcome.
When refractive adaptation is translated into a clinical
setting, it has been reported that the recommended 18e22
weeks may, for some patients, delay treatment. Norris et al.
[10], recommend that patients should be reassessed at 6 and
14 weeks and if there is no significant improvement they
suggest prescribing other forms of treatment. This highlights
the need for further research into refractive treatment for
example a RCT comparing refractive adaptation and other
treatment modalities for amblyopia.Occlusion
How much?
The use of occlusion therapy is the most well-known and
commonly practiced way of treating amblyopia. Until occlu-
sion therapy was prescribed based on clinical experience
rather than scientific based evidence. This generated a wide
variance between departments on how amblyopic patients
were treated clinically [14]. In 1998, the PEDIG [15] sought to
review the number of hours prescribed by recruiting, moder-
ate and severe strabismic and anisometropic amblyopes into
two groups with the moderate amblyopes receiving either 6 h
or 2 h of occlusion, whereas the severe amblyopes received
either full time (all or all but 1 h 4/day) or 6 h of occlusion
[16,17]. Their results revealed that visual outcomes with more
intensive occlusion, 6 h for moderate amblyopes and full time
for severe amblyopes, were similar to the lower amount of
prescription 2 h and 6 h respectively. In addition, their find-
ings revealed no significant difference between cause of
amblyopia and improvement in visual acuity (p ¼ 0.85).
Guidelines from the American Academy of Ophthalmologist
[18] and the Royal College of Ophthalmologist [19] have
changed as a result of these findings so that now both advise
the use of 6 h for severe amblyopia and 2 h for moderates.
Although at present there is still a wide variance in the
number of hours of occlusion prescribed by those treating
amblyopia.
Adherence to occlusion
There is some concern with basing guidelines on the PEDIG
studies because adherence to occlusion therapy is less than
optimal. Therefore, the results shown by the PEDIG group
have been challenged by the work objectively exploring
compliance in amblyopia treatment with the use of occlusion
dose monitors (ODMs) [20,21]. In one study, it was shown that
patients who were prescribed 6 h or 3 h a day only adhered to
half of their prescribed amount, average 2 h 33 min and 1 h
45 min respectively, leading to there being no significant dif-
ference in the total amount of occlusion therapy undertaken
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by another study [11].
Dose response relationships between hours of effective
patching measured by ODMs and visual outcome revealed a
strong correlation up to 6 h in a study including 52 participants
(F ¼ 17.1, p ¼ 0.00013, r ¼ 0.50) [21]. However, in a study with
more participants (n ¼ 97), where refractive adaptation was
prescribed prior to occlusion, dose response relationship pla-
teaued around 4 h particularly in children <4 years [11]. Older
children (older than 6 years) required a higher average of 5.55
(4.45e6.45) h/day of occlusion although this was not signifi-
cantly different to the amountnecessary for<4 years. Similarly,
patients with strabismic amblyopia required more hours of
occlusion therapy thananisometropicamblyopes (5.79 and 5.19
respectively) but again this was not significant. A limitation of
this study was the inclusion of patients with a difference in vi-
sual acuity between the eyes of 0.1, which is lower than the
usually defineddifferenceof 0.2 or even 0.3 asused in the PEDIG
studies. Recently, in unpublished work where participants did
not have prolonged refractive adaptation, a significant dose
response relationship was found up to 10 h for strabismic and
strabismus with anisometropia amblyopes but not in aniso-
metropes [22]. Further evidence is required to explore the pos-
sibility of differing treatment based on the type of amblyopia.
Studies have also begun exploring reasons for poor adher-
ence to occlusion therapy in order to produce better compli-
ance. In 2006, Dixon-Wood et al. [23] interviewed 25 parents of
children who underwent occlusion therapy in order to find
reasons for reduced compliance. A number of key themeswere
highlighted including parents being unsure about the benefits
of treatment, difficulties with distress in the child who was
patching and relationship pressures particularly in the early
stages of treatment. Parents were also asked for suggestions
that could help compliance. Many recommended the use of
rewards, establishing routine, decoration of the patch or
educational cartoons [24]. From this advice, many research
groups have initiated the development of intervention mate-
rial. Tjiam et al. [25] reported using several intervention mate-
rials in low-socioeconomic groups, including cartoons, reward
calendars and parent information leaflets. The result showed
that cartoons produce a significant improvement in compli-
ance in comparison to a control group. In another study by
Pradeep et al. [26], two groups of patients, a control group and a
intervention group, were prescribe 10 h/day of occlusion ther-
apy and were reviewed 12 weeks later. Although the overall
compliance between the two groups was similar, the inter-
ventionmaterial significantly reduced the number of drop-outs
and reduced the number of poorly compliant patients.
Additional studies have explored ways of improving visual
outcomes through increasing the stimulation of the ambly-
opic eye during occlusion. In a pilot RCT study published by
the PEDIG group [27], which included 64 children, with various
types of amblyopia, aged 3 to <7 years, showed that 2 h of
occlusion with advised near tasks did suggest an increase in
visual outcome in comparison to those who were not advised
to undertake near activities while patching. Later with a larger
number of amblyopes (n ¼ 425) and longer follow-up (up to 17
weeks), the same authors reported that occlusion with near
task was insignificant [28]. Another group reported subjects
who underwent 3 h or 6 h occlusion therapy with near tasksand again showed undertaking near tasks while patching
significantly improved visual outcomes [29]; however, greater
numbers are needed to compare to the larger PEDIG study.
Partial occlusion therapy has also been suggested to help
with compliance in the form of Bangerter foils, semi-opaque
foils that can be attached to the glasses. However, in a RCT
comparing Bangerter foils to glasses alone or occlusion, there
was no significant difference in visual outcome for any cause of
amblyopia [30]. It is suggested however that in comparison to
occlusion, Bangerter foilsdoprovide lessdistress for thepatient
and therefore could be considered as a possible alternative.
Recurrence
A challenge of amblyopia treatment is recurrence of amblyopia
on cessation of treatment. It is reported that 13e24% of pa-
tients decrease by 2 or more LogMAR lines within the 1st year
of completing treatment [31e34]. A number of factors have
been associated with this recurrence including better vision at
the end of treatment, greater improvement during treatment,
history of recurrence and a combination of strabismus with
and without anisometropia or microtropia, a small angled
strabismus with abnormal binocular functions. An additional
inverse relationship has also been found between recurrence
and age [31]. In a clinical setting, it has been suggested that
patients should undergo a period of maintenance or weaned
occlusion. Initial research suggests that moderate patching
treatment (6e8 h of occlusion) should undergo a period of
weaning [32]. However, in the only reported RCT of 20 patients
who underwent full-time occlusion, there was no significant
difference between the number of patients inwhich amblyopia
recurred, with and without weaning treatment [34]. A larger
RCT is required to re-affirm this finding.
Critical period
Recent reports have challenged the clinical perception that
amblyopes cannot be treated beyond the critical period, sug-
gested to be around the age of 8 years of age. A large multi-
center study by PEDIG in 2005 [35] revealed that 50% of
children aged between 7 and 12 years of age who underwent a
period of amblyopia treatment, such as occlusion or atropine,
had a significant improvement in visual outcome in compar-
ison to a control group who were only prescribed glasses. The
findings however were not significant for >12 years, but there
was a suggestion that children who had not yet undergone
treatment could also improve. Type of amblyopia, either
anisometropic and/or strabismic was found not to be a pre-
dictor of visual outcome.Atropine
With the increasing knowledge of poor compliance during
patching and the potential cause of social deprivation as result
of occlusion therapy [36], atropine is often used in clinic as an
alternative to occlusion. The role of atropine is to blur the
vision in the nonamblyopic eye by paralyzing the ciliary
muscles that control accommodation and constriction of the
pupil. Although this treatment has been recommended since
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apy, there were no previous RCTs. Largemulticenter RCT have
revealed a number of previously unknown benefits including
the use of atropine being instilled only at the weekends pro-
ducing similar visual outcomes toweekday instillation and the
finding that severe amblyopes can also be treated effectively
[37]. The final point, however, is surprising as it has been re-
ported that atropine can only blur visual acuity to amaximum
of 20/100 in thenonamblyopic eye [38]. The treatment of severe
amblyopia with atropine still requires further investigation as
at present this is limited to an RCT comparing the effects of 2 h
of occlusion therapy and atropine in children 7e12 years. This
does not accurately reflect the amount of occlusion suggested
for severe amblyopia particularly in this older age group [39].
A greater amount of research has been undertaken inves-
tigating the treatment ofmoderate amblyopeswith atropine in
comparison to occlusion. Comparisons between occlusion and
atropine at long-term outcomes are reported to have a similar
visual outcome in moderate amblyopes. Occlusion therapy
(minimum 6 h a day to maximum 10 h a day) was revealed to
have a quicker initial, although not significant, improvement
in vision in comparison to the atropine group [40e42]. Sub-
group analysis of type of amblyopia has no effect on long-term
visual outcomes (p ¼ 0.83). Despite the equivalent outcomes
between occlusion and atropine, atropine is still commonly
only used as a secondary option after occlusion has been un-
successful, usually as a result of poor compliance [9]. Even
though atropine is reported to be better tolerated and a less
emotional experience than occlusion therapy [43], it is not
clear whether occlusion therapy could achieve better visual
outcomes than atropine, especially if adherence to occlusion is
optimized with the use of intervention.Perceptual learning
The idea of perceptual learning was first defined by Eleanor
Gibson (1963) and involved training patients on perceptual
tasks with the Cambridge Visual Stimulator (CAM) a system
that used high contrast rotating sine-wave gratings [44]. The
use of CAM significantly decreased when little benefit in
comparison to occlusion therapy was found [45]. With the
availability and improvements of computers, perceptual
learning has begun to regain increasing interest, particularly
in patients beyond the critical period. During perceptual
learning, patients are often trained on contrast sensitivity
tasks while nonamblyopic eye is occluded [46,47]. More recent
game play formats have also been used to increase stimula-
tion of the amblyopic eye [48,49]. Initial results report a sig-
nificant improvement in visual outcome in the amblyopic eye
[48e50]. The limitation of many perceptual learning studies is
the lack of large scale, RCTs with long term follow-up. Two
studies have followed-up subjects after monocular and
binocular treatment. Both studies show a decline in visual
outcomes after 8e10 weeks although less significant in the
binocular group [49,51]. In addition, due to low study number,
sub-analysis of amblyopia cause has not yet been undertaken.
Moreover, very few studies report the size of the strabismic
deviation except Li et al. [50] who recruited 3/10 strabismic
subjects of a deviation greater than 10 prism dioptres.An adaption of perceptual learning is to use stimulation to
both eyes to treat amblyopia [51]. During treatment, an image
is presented to both eyes, the dominant eye is presented with
a low contrast eye while the amblyopic eye is given a high
contrast eye. If subjects are successful in completing the
game, the image in the dominant eye is slowly increased until
the contrast in both eyes is equal. Patients are trained using a
dichoptic game format, usually Tetris. This game requires the
use of both eyes by presenting only half the blocks to each eye.
Pilot data show promising results with improvements in vi-
sual outcome and stereopsis in the majority of patients. The
stereopsis outcomes have also been reported to be enhanced
using transcranial direct current stimulation [52]. However,
due to the current sample size in both studies, no analysis was
undertaken to explore the effects of the cause of amblyopia on
visual outcome. Moreover, the size of strabismic deviations in
strabismic subjects was also not reported. Further analysis
with greater number of subjects would help to establish
suitable subtypes of amblyopia that would benefit from this
form of treatment.Pharmacological treatment
Levodopa is the most commonly reported medical drug used
in amblyopia treatment and is a precursor to dopamine.
Dopamine is a neurotransmitter present within the visual
pathwaywhich has been shown,with the use of animalmodel
[53], to be reduced in amblyopia. In 1990, Gottlob and Stangler-
Zuschrott [54] first described the use of levodopa in severe
strabismic and strabismic with anisometropia amblyopia and
reported a significant improvement in suppression scotomas
and contrast sensitivity outcomes when treated with levo-
dopa. Improvements in other visual functions, including vi-
sual acuity, have been reported in a number of studies [55,56]
and are enhanced by the use of occlusion therapy and carbi-
dopa, which increases levodopa uptake into the bloodebrain
barrier [57]. Regression of VA outcomes after ceasing levodopa
are high although more sustained in those who receive full-
time occlusion and are younger (3e7 years) [58e60]. In all
studies except one, all forms of amblyopia were recruited into
the study. Due to the sample sizes, no analysis based on type
of amblyopia was performed. Side effects from levodopa are
commonly reported in literature and limit its use in a clinical
setting however further work, suggested by the PEDIG group,
in the form of a placebo-control trial is warranted.
Recent discoveries in mice have shown that the lynx1 gene
codes for a protein that suppresses acetylcholine receptor
signaling in the brain and regulates plasticity of the mature
brain [61]. Cholinesterase inhibitors may prevent the expres-
sion of lynx1 allowing for plasticity in the brain beyond the
critical period thatwould be beneficial in amblyopia treatment
and has already begun to form the basis of future research.Acupuncture
The use of acupuncture for the treatment of medical condi-
tions has long been discussed in the literature but has only
relatively recently been applied to amblyopia treatment.
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flow in the visual cortex through accurate stimulation using
the correct acupoints [62]. Currently, two RCT using
acupuncture in amblyopia treatment have been reported. The
initial study reported the results of two groups of anisome-
tropic amblyopes aged 7e12 years. The first group received
acupuncture while the second group (control groups) received
2 h of occlusion therapy. At 15weeks, follow-up subjects in the
acupuncture group were found to have significantly greater
improvements in visual acuity in comparison to the control
group (2.27 lines and 1.83 lines respectively) [63].
More recently, Lam et al. [64] reported the effects of
acupuncture on anisometropic children aged 3e7-year-old
who were undergoing refractive adaption. Using a random-
ized cross-over trial method, they found significantly greater
improvements in visual acuity in the phases that corre-
sponded with the use of acupuncture. Although both studies
revealed a benefit of acupuncture a significant limitation was
absence of a control group to assess for placebo effect. An
additional limitation in the first study was that the acupunc-
ture group required more clinical visits than the occlusion
group leading to a possible Hawthorne effect (positive atten-
tion bias). These limitations would need to be further
addressed before implementation into clinical practice
particularly in areas where acupuncture is not a common
treatment in any medical condition.Other treatments
Several other suggestions have been reported as an alterna-
tive to the conventional treatment for amblyopia. Many have
developed in order to address the issue with poor compliance
to either glasses or occlusion therapy [65e67]. Very few have
been translated into clinical practice although significant
improvements have been noted in refractive surgery and
occlusive contact lenses treatment. The main concern is the
increased risk that many of these suggested treatments have
in comparison to occlusion therapy. Although refractive sur-
gery has proven successful in adults, it is not clear what long-
term effects it has on young children particularly when the
eye is still continuing to develop. An additional difficulty is
compliance with maintenance issues particularly with con-
tact lenses where good hygiene practice is required [67].
Other more controversial nonrandomized prospective tri-
als have reported the use of sutured occluders or silicone lid
closures to promote the use of the weaker eye [68,69]. With
high-risk of reversal amblyopia, lasting long-term effects and
no control group, it is difficult to warrant their merit in com-
parison to occlusion.Conclusion
Since the Snowdon's report, amblyopia research has advanced
significantly particularlywith theuse of randomized controlled
trials. However, while revealing that refractive adaptation, oc-
clusion and penalization can improve visual acuity in ambly-
opia this has led to the raising of additional questions that
require further investigation. Compliance issues remain asignificant problem, although studies have positively
addressed this by increasing the amount of information pro-
vided to families. With the increasing knowledge of the role
occlusion and glasses plays individually in the improvement of
the amblyopic eye, research should continue to find more
specific treatment protocols for the various types of amblyopia.
Further, RCTs are required to investigate these relationships.
Additional research could also help to provide more reli-
able treatment options. With the growing public interest in
binocularity and computer systems, treating amblyopes with
game-play could potentially initiate a new form of amblyopia
treatment. It is, however, important that these treatment
methods undergo robust clinical trials so that further clarifi-
cation of the types of amblyopia that will benefit with game-
play treatments can be established. RCTs between binocular
treatments and occlusion therapy are also still warranted.
In conclusion, although advancements have been made,
further research is still required to help those treating
amblyopia particularly in regards to improvement and main-
taining compliance to treatment. Research in the area of
refractive correction compliance, binocular treatment and
more education on atropine is also needed. However, since
the Snowdon's report, we now have reliable scientific evi-
dence to show that prescribing refractive correction and
atropine or occlusion with additional interventional material
should optimize visual outcomes in amblyopic patients with
minimal side effects.Source of support
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